Opko Health (OPK) Research & Development (2010 - 2026)

Opko Health (OPK) has reported Research & Development for 17 consecutive years, with $29.2 million the latest figure, recorded in Q1 2026.

• Research & Development for Q1 2026 came in at $29.2 million, down 5.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $122.4 million (up 15.87% YoY), and the FY2025 annual result was $124.0 million, up 17.89% from the prior year.
• Research & Development was $29.2 million for Q1 2026 at Opko Health, down from $32.8 million in the prior quarter.
• Over five years, Research & Development peaked at $32.8 million in Q4 2025 and troughed at $17.3 million in Q2 2022.
• Average Research & Development over 5 years is $24.5 million, with a median of $23.0 million recorded in 2024.
• Year-over-year, Research & Development jumped 78.05% in 2023 and plunged 32.72% in 2024.
• Over 5 years, Research & Development stood at $19.5 million in 2022, then slipped by 0.69% to $19.4 million in 2023, then soared by 48.34% to $28.8 million in 2024, then climbed by 13.91% to $32.8 million in 2025, then dropped by 10.9% to $29.2 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $29.2 million in Q1 2026, $32.8 million in Q4 2025, and $30.1 million in Q3 2025.